Study of Biomarkers and Outcomes in Early Psychosis Disorders Including Schizophrenia, Bipolar I, and Related Conditions With Coordinated Specialty Care Treatment

What this Trial Is About

Researchers are studying the early stages of psychotic disorders such as Schizophrenia, Schizoaffective Disorder, and Bipolar I Disorder to better understand their progression and how biological markers and different patient types may predict treatment response. This observational study involves a large sample across multiple sites, aiming to identify clinical and biological predictors of outcomes to improve personalized care for individuals with early psychosis. Participants receive coordinated specialty care and undergo a series of assessments including brain scans MRI, eye-tracking, EEG, DNA collection, and neuropsychological testing at baseline and follow-up visits at 1, 6, and 12 months. These procedures help gather data on brain function, genetics, and cognitive abilities. The study categorizes participants into biotypes based on biomarker profiles to explore their relation to treatment outcomes. Participants are involved for about one year, attending four visits where clinical interviews, cognitive tests, and biomarker assessments are conducted. Screening takes about three hours and includes drug and pregnancy testing, psychiatric and medical history reviews. Researchers track outcomes such as treatment response, symptomatic and functional remission, and relapse over the study period to gain insight into early psychosis and guide future care strategies.

Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services